Medical Device Regulation in India

A medical device is any instrument, machine, implant or material used to find, prevent, watch or treat a disease or injury, where it works mainly in a physical way rather than as a chemical medicine. A thermometer, a syringe, a blood pressure monitor, a CT scanner, a heart stent and a pacemaker are all medical devices. Medical device regulation means the laws and rules that make sure these devices are safe, work as promised and are made to proper quality.

Why does it matter?

A faulty medicine can harm a patient, and so can a faulty device. A heart valve that breaks, a hip implant that wears out early or a ventilator that stops working can cost lives. For many years, most medical devices in India were not properly regulated. Regulation protects patients, builds trust in Indian products and helps Indian companies export to other countries that demand strict quality.

Where did it come from?

For a long time India had no separate law for devices. Only a few devices were "notified" as drugs and regulated under the Drugs and Cosmetics Act, 1940. Step by step, this changed:

• December 2014: the government allowed 100% Foreign Direct Investment (FDI) through the automatic route in medical device manufacturing, to attract global makers.
• 2017: the Medical Devices Rules, 2017 were issued under the Drugs and Cosmetics Act. They came into force on 1 January 2018. This was India's first full set of rules just for medical devices.
• February 2017 and August 2017: the National Pharmaceutical Pricing Authority (NPPA) capped the prices of coronary stents and then knee implants, cutting prices sharply. The first stent caps were ₹29,600 for drug-eluting stents and ₹7,260 for bare-metal stents. (A drug-eluting stent slowly releases a medicine to keep the artery open; a bare-metal stent has no coating.)
• 1 April 2020: a notification dated 11 February 2020 brought all medical devices under the definition of "drugs" in Section 3(b)(iv) of the 1940 Act, so every device came under regulation. From the same date, the NPPA also brought all devices under price monitoring by the Drugs (Prices Control) Order, 2013 (DPCO). Devices without a price cap can raise their MRP by at most 10% a year.
• 2022 and 2023: licensing became compulsory in phases: from 1 October 2022 for low-risk devices (Class A and B) and from 1 October 2023 for higher-risk devices (Class C and D).
• April 2023: the Union Cabinet approved the National Medical Devices Policy, 2023, to grow the sector from about $11 billion to $50 billion by 2030.
• November 2026: the government extended the PLI Scheme for Medical Devices up to 2035-36 as PLI-MD 2.0 and invited fresh applications.

How are devices classified?

The Medical Devices Rules, 2017 put devices into four classes based on risk. The higher the risk, the stricter the checks. Think of it like a driving licence: a bicycle needs none, a scooter needs a simple licence, and a heavy truck needs the strictest test.

• Class A (low risk): for example, bandages and tongue depressors.
• Class B (low to moderate risk): for example, hypodermic needles and suction equipment.
• Class C (moderate to high risk): for example, lung ventilators and bone fixation plates.
• Class D (high risk): for example, heart valves and implantable pacemakers.

Who does what?

• The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), is the Central Licensing Authority. It licenses the manufacture of Class C and D devices and the import of all devices.
• State drug controllers act as State Licensing Authorities for making Class A and B devices.
• Notified Bodies, which are approved private agencies, audit the factories of Class A and B makers on behalf of the regulator.
• The Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers) handles industry promotion: PLI, parks and policy. The NPPA handles prices.

How is India helping the industry grow?

India imports about 70% of its medical devices, and much more for high-end items like implants and imaging machines. To change this, the government has used several tools:

• PLI Scheme for Medical Devices (2020, ₹3,420 crore): pays 5% of extra sales for five years in four segments: cancer care and radiotherapy, radiology and imaging, anaesthetics and cardio-respiratory devices, and implants. PLI stands for Production Linked Incentive: the government pays a company a small share of its extra sales of goods made in India.
• PLI-MD 2.0 (November 2026): the same scheme, extended up to 2035-36, with about ₹2,700 crore available for new applicants. It drops the minimum sales a company needed to claim the incentive and lowers the minimum investment. Applicants get three years to set up factories in any of the four segments. Incentives are about 5% for consumables, disposables and implants, 6% for devices now assembled in India, and about 9% for critical components and some high-end machines. It aims to make machines in India that are not made here yet, such as 3T MRI and PET-CT scanners and ultrasound probes.
• Scheme for Promotion of Medical Device Parks (₹400 crore; up to ₹100 crore per park): four parks in Himachal Pradesh (Nalagarh), Madhya Pradesh (Ujjain), Tamil Nadu (Kancheepuram) and Uttar Pradesh (Greater Noida, in the Yamuna Expressway area). These give shared testing labs and facilities so small firms need not build everything themselves.
• National Medical Devices Policy, 2023: aims for the sector to reach $50 billion by 2030. It focuses on smoother regulation, infrastructure, research and innovation, investment, skilling and brand building.
• Scheme for Strengthening of Medical Device Industry (launched 8 November 2024, ₹500 crore, FY 2024-25 to FY 2026-27): five sub-schemes for common facilities in clusters, marginal investment to cut import dependence, skill development, support for clinical studies and industry promotion. It mainly helps MSMEs and startups.

Commonly confused concepts

• Medical device vs drug: a drug works mainly by chemical action inside the body. A device works mainly in a physical or mechanical way. Legally, however, India regulates devices under the Drugs and Cosmetics Act, because Section 3(b)(iv) counts notified devices as "drugs".
• CDSCO vs NPPA: CDSCO checks safety and quality and gives licences. NPPA controls prices. They are under different ministries (Health and Chemicals and Fertilizers respectively). NPPA fixes a ceiling price for a few devices, such as stents and knee implants. For all other devices, it only checks that the MRP does not rise by more than 10% a year.
• PLI for Medical Devices vs Medical Device Parks scheme: PLI rewards companies for extra sales. The parks scheme gives grants for shared infrastructure in selected states.
• Class A vs Class D: Class A is the lowest risk and is licensed at the state level. Class D is the highest risk and is licensed by the central regulator.

Issues, criticism and the way forward

• No separate law: devices are still regulated under a law written for medicines in 1940. Many experts and industry bodies want a separate law and a separate regulator for devices, since devices involve engineering and software, not chemistry. A draft Drugs, Medical Devices and Cosmetics Bill was released in 2022 for this purpose.
• High import dependence: high-end devices and key parts such as electronic components and sensors are still largely imported. The trade gap has stayed large.
• Price control vs innovation: price caps on stents and knee implants made them affordable for patients. But some companies said the caps reduced their interest in launching newer models in India.
• Capacity of the regulator: licensing every device needs many trained inspectors and testing labs. Shortages cause delays.
• Newer technology: software and artificial intelligence tools used in diagnosis are now counted as medical devices. Rules for them are still evolving.
• Way forward: a dedicated device law and regulator, more testing labs, support for research, quicker clearances and stronger links between hospitals, engineers and industry are commonly suggested.

Concepts to Know

• Implant: a device placed inside the body, such as a heart stent, knee joint or pacemaker.
• Automatic route (FDI): foreign companies can invest without first asking the government for permission; they only need to inform the RBI.
• Notified Body: a private agency approved by the regulator to inspect and audit factories on its behalf.
• Linear Accelerator (LINAC): a machine that gives high-energy radiation to kill cancer cells.
• Cath Lab: a hospital room with special imaging machines used to look at and treat the heart's blood vessels, for example to insert a stent.
• Drugs (Prices Control) Order, 2013 (DPCO): a government order made under the Essential Commodities Act, 1955. It lets the NPPA fix ceiling prices and watch price rises of medicines and devices.
• MRP (Maximum Retail Price): the highest price a shop can charge you. It is printed on the pack.
• Critical components: the key inner parts of a machine, such as sensors, detectors and circuit boards. India imports most of them today.
• 3T MRI: an MRI scanner uses a strong magnet to take detailed pictures inside the body. "3T" (3 Tesla) means a very strong magnet, which gives sharper pictures.
• PET-CT: a scanner that joins two tests in one. The PET part shows how active the body's cells are, which helps find cancer; the CT part shows exactly where they are.